Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 3168.

https://doi.org/10.1182/blood.V128.22.3168.3168

Published: 2016

Journal Articles

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

Nianhang Chen, Abderrahmane Laadem, MD, Dawn M. Wilson, Xiaosha Zhang, Matthew L. Sherman, MD, Steve Ritland, Kenneth M. Attie, MD

Blood (2016) 128 (22): 1990.

https://doi.org/10.1182/blood.V128.22.1990.1990

Published: 2016

Journal Articles

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 5551.

https://doi.org/10.1182/blood.V128.22.5551.5551

Published: 2016

Journal Articles

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

Nianhang Chen, Abderrahmane Laadem, MD, Dawn M. Wilson, Xiaosha Zhang, Matthew L. Sherman, MD, Steve Ritland, Kenneth M. Attie, MD

Blood (2016) 128 (22): 2463.

https://doi.org/10.1182/blood.V128.22.2463.2463

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 92.

https://doi.org/10.1182/blood.V126.23.92.92

Published: 2015

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 2862.

https://doi.org/10.1182/blood.V126.23.2862.2862

Published: 2015

Journal Articles

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Goetze, MD, Philipp Kiewe, MD, Karin Mayer, MD, Oliver Ottman, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 411.

https://doi.org/10.1182/blood.V124.21.411.411

Published: 2014

Journal Articles

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Antonio G. Piga, MD, Silverio Perrotta, MD, Angela Melpignano, MD, Caterina Borgna-Pignatti, MD, Ersi Voskaridou, MD, Vincenzo Caruso, MD, Aldo Filosa, MD, Yesim Aydinok, MD, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 53.

https://doi.org/10.1182/blood.V124.21.53.53

Published: 2014

Journal Articles

ACE-536 Increases Hemoglobin in Healthy Postmenopausal Women: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study

Kenneth M Attie, MD, Ingrid E Boyd, Dawn M Wilson, Mark J Allison, MD, CPI, Matthew L Sherman, MD

Blood (2012) 120 (21): 3194.

https://doi.org/10.1182/blood.V120.21.3194.3194

Published: 2012

NARROW

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

ACE-536 Increases Hemoglobin in Healthy Postmenopausal Women: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only